FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2405978044> ?p ?o ?g. }

• W2405978044 endingPage "105" @default.
• W2405978044 startingPage "93" @default.
• W2405978044 abstract "Hip fracture is an important and costly problem. Therapy with the bisphosphonate risedronate effectively prevents hip and other fractures among women with established osteoporosis. Risedronate is a first-choice therapy option in the German Guidelines of the Dachverband Osteologie for Osteoporosis according to evidence-based medicine criteria for the treatment of postmenopausal osteoporosis, osteoporosis of the elderly (women aged > 75 years) and glucocorticoid-induced osteoporosis. There are few published economic evaluations of bisphosphonates in Germany. Therefore, an assessment of the cost-effectiveness of risedronate utilizing a state transition Markov model of established postmenopausal osteoporosis based on randomized clinical trial data was developed. Uncertainty underlying model parameters and outcomes was dealt with using traditional sensitivity analysis and stochastic sensitivity analysis to produce quasi-95% Cls. We focused on patients aged 70 years, since this population most closely matches the randomized controlled trial and is typical of osteoporosis patients in Germany. The baseline model was a cohort of 1,000 70-year-old women, who received risedronate for 3 years and were followed up for an overall observation period of 10 years, modelling transitions through estimated health states and evaluating outcomes. Over the 3-year treatment period and 10-year observation period, risedronate dominated the current average basic treatment in Germany. In the risedronate group 33 hip fractures were averted and 32 quality-adjusted life years (QALYs) were gained (discounted values). Risedronate treatment saves costs for German social insurance: the present net value of the associated costs from the perspective of German social insurance is [symbol: see text]10.66 million if risedronate treatment is used versus [symbol: see text]11 million if basic treatment is used. Thus, net savings of [symbol: see text]340,000 for the treatment group per 1,000 treated women were calculated. Furthermore, risedronate treatment is cost effective from the perspective of the statutory health insurance with costs per averted hip fracture in the analyzed population of [symbol: see text]33,856 and cost per QALY gained of [symbol: see text]35,690. Both results demonstrate cost-effectiveness and are far below the accepted threshold level of [symbol: see text]50,000. Based on this analysis, risedronate is a cost-effective treatment for postmenopausal osteoporosis within the German health care system, offering benefits for osteoporotic patients and for budget decision-makers." @default.
• W2405978044 created "2016-06-24" @default.
• W2405978044 creator A5039037110 @default.
• W2405978044 creator A5050257893 @default.
• W2405978044 creator A5064797857 @default.
• W2405978044 creator A5071132796 @default.
• W2405978044 creator A5079801911 @default.
• W2405978044 creator A5091109901 @default.
• W2405978044 date "2003-01-01" @default.
• W2405978044 modified "2023-09-26" @default.
• W2405978044 title "Pharmacoeconomic analysis of osteoporosis treatment with risedronate." @default.
• W2405978044 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15224498" @default.
• W2405978044 hasPublicationYear "2003" @default.
• W2405978044 type Work @default.
• W2405978044 sameAs 2405978044 @default.
• W2405978044 citedByCount "12" @default.
• W2405978044 countsByYear W24059780442012 @default.
• W2405978044 countsByYear W24059780442022 @default.
• W2405978044 crossrefType "journal-article" @default.
• W2405978044 hasAuthorship W2405978044A5039037110 @default.
• W2405978044 hasAuthorship W2405978044A5050257893 @default.
• W2405978044 hasAuthorship W2405978044A5064797857 @default.
• W2405978044 hasAuthorship W2405978044A5071132796 @default.
• W2405978044 hasAuthorship W2405978044A5079801911 @default.
• W2405978044 hasAuthorship W2405978044A5091109901 @default.
• W2405978044 hasConcept C112930515 @default.
• W2405978044 hasConcept C126322002 @default.
• W2405978044 hasConcept C168563851 @default.
• W2405978044 hasConcept C1862650 @default.
• W2405978044 hasConcept C187212893 @default.
• W2405978044 hasConcept C2776541429 @default.
• W2405978044 hasConcept C2777251235 @default.
• W2405978044 hasConcept C2781104859 @default.
• W2405978044 hasConcept C2908647359 @default.
• W2405978044 hasConcept C3019080777 @default.
• W2405978044 hasConcept C64332521 @default.
• W2405978044 hasConcept C71924100 @default.
• W2405978044 hasConcept C72563966 @default.
• W2405978044 hasConcept C99454951 @default.
• W2405978044 hasConceptScore W2405978044C112930515 @default.
• W2405978044 hasConceptScore W2405978044C126322002 @default.
• W2405978044 hasConceptScore W2405978044C168563851 @default.
• W2405978044 hasConceptScore W2405978044C1862650 @default.
• W2405978044 hasConceptScore W2405978044C187212893 @default.
• W2405978044 hasConceptScore W2405978044C2776541429 @default.
• W2405978044 hasConceptScore W2405978044C2777251235 @default.
• W2405978044 hasConceptScore W2405978044C2781104859 @default.
• W2405978044 hasConceptScore W2405978044C2908647359 @default.
• W2405978044 hasConceptScore W2405978044C3019080777 @default.
• W2405978044 hasConceptScore W2405978044C64332521 @default.
• W2405978044 hasConceptScore W2405978044C71924100 @default.
• W2405978044 hasConceptScore W2405978044C72563966 @default.
• W2405978044 hasConceptScore W2405978044C99454951 @default.
• W2405978044 hasIssue "4" @default.
• W2405978044 hasLocation W24059780441 @default.
• W2405978044 hasOpenAccess W2405978044 @default.
• W2405978044 hasPrimaryLocation W24059780441 @default.
• W2405978044 hasRelatedWork W143185114 @default.
• W2405978044 hasRelatedWork W1526826623 @default.
• W2405978044 hasRelatedWork W1968058470 @default.
• W2405978044 hasRelatedWork W1968719103 @default.
• W2405978044 hasRelatedWork W1970400080 @default.
• W2405978044 hasRelatedWork W1982513519 @default.
• W2405978044 hasRelatedWork W1997477353 @default.
• W2405978044 hasRelatedWork W2014026657 @default.
• W2405978044 hasRelatedWork W2032481698 @default.
• W2405978044 hasRelatedWork W2042887042 @default.
• W2405978044 hasRelatedWork W2050587934 @default.
• W2405978044 hasRelatedWork W2054983767 @default.
• W2405978044 hasRelatedWork W2078207681 @default.
• W2405978044 hasRelatedWork W2102123887 @default.
• W2405978044 hasRelatedWork W2107177566 @default.
• W2405978044 hasRelatedWork W2124367022 @default.
• W2405978044 hasRelatedWork W2124527463 @default.
• W2405978044 hasRelatedWork W2153009489 @default.
• W2405978044 hasRelatedWork W2153538330 @default.
• W2405978044 hasRelatedWork W2161837912 @default.
• W2405978044 hasVolume "23" @default.
• W2405978044 isParatext "false" @default.
• W2405978044 isRetracted "false" @default.
• W2405978044 magId "2405978044" @default.
• W2405978044 workType "article" @default.